Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GDRX Stock Forecast 2026-2027
$2.24
Current Price
$767.37M
Market Cap
Buy 5
Hold 8
Sell 2
Wall St Analyst Ratings
Distance to GDRX Price Targets
+56.3%
To High Target of $3.50
+33.9%
To Median Target of $3.00
-15.2%
To Low Target of $1.90
GDRX Price Momentum
-1.8%
1 Week Change
+2.8%
1 Month Change
-49.3%
1 Year Change
-17.3%
Year-to-Date Change
-61.4%
From 52W High of $5.81
+26.6%
From 52W Low of $1.77
📊 TOP ANALYST CALLS
Did GDRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if GoodRx is one of their latest high-conviction picks.
Latest GDRX Stock Price Targets & Analyst Predictions
Based on our analysis of 27 Wall Street analysts, GDRX has a neutral consensus with a median price target of $3.00 (ranging from $1.90 to $3.50). The overall analyst rating is Buy (6.9/10). Currently trading at $2.24, the median forecast implies a 33.9% upside. This outlook is supported by 5 Buy, 8 Hold, and 2 Sell ratings.
The most optimistic forecast comes from Stan Berenshteyn at Wells Fargo, projecting a 56.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GDRX Analyst Ratings
5
Buy
8
Hold
2
Sell
GDRX Price Target Range
Low
$1.90
Average
$3.00
High
$3.50
Current: $2.24
Latest GDRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GDRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 4, 2026 | Wells Fargo | Stan Berenshteyn | Overweight | Maintains | $3.50 |
| Mar 3, 2026 | Citigroup | Daniel Grosslight | Buy | Maintains | $3.50 |
| Mar 2, 2026 | Goldman Sachs | Eric Sheridan | Neutral | Maintains | $2.50 |
| Feb 27, 2026 | Mizuho | Steven Valiquette | Neutral | Maintains | $3.00 |
| Feb 27, 2026 | JP Morgan | Lisa Gill | Neutral | Downgrade | $N/A |
| Jan 22, 2026 | Jefferies | Glen Santangelo | Hold | Downgrade | $2.75 |
| Jan 9, 2026 | Citigroup | Daniel Grosslight | Buy | Maintains | $4.50 |
| Dec 18, 2025 | Morgan Stanley | Craig Hettenbach | Equal-Weight | Maintains | $4.00 |
| Dec 9, 2025 | Barclays | Glen Santangelo | Underweight | Initiates | $3.00 |
| Nov 11, 2025 | JP Morgan | Lisa Gill | Overweight | Maintains | $5.00 |
| Nov 10, 2025 | TD Cowen | Charles Rhyee | Buy | Maintains | $6.00 |
| Nov 6, 2025 | UBS | Kevin Caliendo | Neutral | Maintains | $4.00 |
| Nov 6, 2025 | Mizuho | Steven Valiquette | Neutral | Maintains | $4.00 |
| Aug 11, 2025 | UBS | Kevin Caliendo | Neutral | Maintains | $4.25 |
| May 13, 2025 | UBS | Kevin Caliendo | Neutral | Maintains | $5.25 |
| May 9, 2025 | Goldman Sachs | Eric Sheridan | Neutral | Maintains | $5.00 |
| Apr 29, 2025 | Wells Fargo | Stan Berenshteyn | Overweight | Maintains | $7.00 |
| Apr 10, 2025 | Truist Securities | Jailendra Singh | Hold | Maintains | $5.50 |
| Feb 28, 2025 | Wells Fargo | Stan Berenshteyn | Overweight | Maintains | $8.00 |
| Jan 10, 2025 | Citigroup | Daniel Grosslight | Buy | Maintains | $6.25 |
GoodRx Holdings, Inc. Class A Common Stock (GDRX) Competitors
The following stocks are similar to GoodRx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GoodRx Holdings, Inc. Class A Common Stock (GDRX) Financial Data
GoodRx Holdings, Inc. Class A Common Stock has a market capitalization of $767.37M with a P/E ratio of 24.8x. The company generates $796.85M in trailing twelve-month revenue with a 3.8% profit margin.
Revenue growth is -1.9% quarter-over-quarter, while maintaining an operating margin of +19.0% and return on equity of +4.5%.
Valuation Metrics
Market Cap
$767.37M
Enterprise Value
$1.04B
P/E Ratio
24.8x
PEG Ratio
6.0x
Price/Sales
1.0x
Growth & Margins
Revenue Growth (YoY)
-1.9%
Gross Margin
+91.0%
Operating Margin
+19.0%
Net Margin
+3.8%
EPS Growth
-19.5%
Financial Health
Cash/Price Ratio
+34.1%
Current Ratio
2.6x
Debt/Equity
88.1x
ROE
+4.5%
ROA
+4.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
GoodRx Holdings, Inc. Class A Common Stock (GDRX) Business Model
About GoodRx Holdings, Inc. Class A Common Stock
What They Do
Healthcare technology company enhancing prescription affordability.
Business Model
The company generates revenue by offering a platform that aggregates prescription pricing, allowing consumers to access discounts and negotiated rates at pharmacies. It also provides subscription-based services, telehealth solutions through GoodRx Care, and partnerships with pharmaceutical manufacturers, thereby diversifying its income streams.
Additional Information
Founded in 2011 and headquartered in Santa Monica, California, the company also caters to the pet health market by offering prescription-related products and services. GoodRx plays a crucial role in promoting price transparency and affordability in the U.S. prescription market, serving various stakeholders including consumers, pharmacies, and life sciences companies.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
697
CEO
Ms. Wendy Barnes
Country
United States
IPO Year
2020
Website
www.goodrx.comGoodRx Holdings, Inc. Class A Common Stock (GDRX) Latest News & Analysis
Latest News
Quick Summary
GoodRx (GDRX) partners with Viatris to offer discounts on 17 brand medications, enabling eligible insured patients to pay as low as $0–$4, and cash-paying consumers to access reduced prices.
Why It Matters
GoodRx's collaboration with Viatris enhances its value proposition, potentially increasing user engagement and revenue while improving access to affordable medications, positively impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
GoodRx (GDRX) announced employer-sponsored access to Zepbound® (tirzepatide) KwikPen® at a set price of $449, allowing self-insured employers to subsidize costs for employees.
Why It Matters
GoodRx's partnership to offer Zepbound at a fixed price enhances its service offerings, potentially increasing user adoption and revenue, positively impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
GoodRx's Q4 earnings highlighted a shift towards self-service in the prescription market, with consumers seeking clearer pricing and faster fulfillment in digital commerce.
Why It Matters
GoodRx's focus on enhancing the prescription experience reflects shifting consumer preferences, potentially driving growth and impacting market competitiveness in digital healthcare.
Source: PYMNTS
Market Sentiment:
Neutral
Quick Summary
GoodRx Holdings, Inc. (GDRX) held its Q4 2025 earnings call, providing financial results and insights into company performance. Details on revenue and forecasts were discussed.
Why It Matters
The Q4 2025 earnings call provides insights into GoodRx's financial performance and future outlook, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
GoodRx Holdings reported Q4 2025 revenue of $194.8 million, with a net income of $5.4 million and an adjusted EBITDA of $65.0 million, reflecting strong financial performance.
Why It Matters
GoodRx's Q4 2025 results show strong revenue and profitability, indicating effective cost management and growth potential, which could attract investor interest and influence stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
GoodRx's Q4 2025 results show performance metrics that should be compared to Wall Street estimates and prior year's figures for a comprehensive assessment.
Why It Matters
GoodRx's performance against Wall Street estimates and previous year's metrics can indicate its growth trajectory and market position, influencing investor sentiment and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About GDRX Stock
What is GoodRx Holdings, Inc. Class A Common Stock's (GDRX) stock forecast for 2026?
Based on our analysis of 27 Wall Street analysts, GoodRx Holdings, Inc. Class A Common Stock (GDRX) has a median price target of $3.00. The highest price target is $3.50 and the lowest is $1.90.
Is GDRX stock a good investment in 2026?
According to current analyst ratings, GDRX has 5 Buy ratings, 8 Hold ratings, and 2 Sell ratings. The stock is currently trading at $2.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GDRX stock?
Wall Street analysts predict GDRX stock could reach $3.00 in the next 12 months. This represents a 33.9% increase from the current price of $2.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is GoodRx Holdings, Inc. Class A Common Stock's business model?
The company generates revenue by offering a platform that aggregates prescription pricing, allowing consumers to access discounts and negotiated rates at pharmacies. It also provides subscription-based services, telehealth solutions through GoodRx Care, and partnerships with pharmaceutical manufacturers, thereby diversifying its income streams.
What is the highest forecasted price for GDRX GoodRx Holdings, Inc. Class A Common Stock?
The highest price target for GDRX is $3.50 from Stan Berenshteyn at Wells Fargo, which represents a 56.3% increase from the current price of $2.24.
What is the lowest forecasted price for GDRX GoodRx Holdings, Inc. Class A Common Stock?
The lowest price target for GDRX is $1.90 from at , which represents a -15.2% decrease from the current price of $2.24.
What is the overall GDRX consensus from analysts for GoodRx Holdings, Inc. Class A Common Stock?
The overall analyst consensus for GDRX is neutral. Out of 27 Wall Street analysts, 5 rate it as Buy, 8 as Hold, and 2 as Sell, with a median price target of $3.00.
How accurate are GDRX stock price projections?
Stock price projections, including those for GoodRx Holdings, Inc. Class A Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 15, 2026 9:06 PM UTC